2024-07-04 09:01:19
Doctors are eagerly awaiting the decision, which they hope will reduce the burden of respiratory syncytial virus (RSV) mortality in older patients. In an opinion published on Thursday 4 July, the Health Service (HAS), the independent body responsible for setting good professional practice, recommended that people aged 65 to 74 years with chronic respiratory disease or heart disease, as well as all people with this condition, People are vaccinated once morest the virus.
Because RSV doesn’t just affect babies, it’s known to cause bronchiolitis in three out of four infants, leading to yearly embolisms in hospital systems. This highly contagious respiratory virus can also cause acute respiratory distress syndrome or serious complications in older adults, such as exacerbation of underlying heart or lung disease or pneumonia that requires breathing assistance.
Although the burden of RSV in this population remains difficult to accurately assess, “We know that this respiratory infection has a large impact on mortality and morbidity, leading to worse health outcomes and significant increases in dependence in older adults.”explains Anne-Claude Crémieux, Chair of the HAS Technical Committee on Vaccination. “The seriousness of RSV infection lies not only in pneumonia but also in decompensation of pre-existing conditions”“, adds the public health professor. Work by the French Public Health Agency using French hospitalization data shows that adults over 75 years old accounted for 61% of RSV-related hospitalizations and 78% of deaths among adults in the winter of 2022-2023 %.
ever-expanding arsenal
This is the latest development in the fight once morest RSV, whose arsenal has continued to expand over the past year. Until then, progress involved babies. In fact, HAS on June 13 validated the vaccination of pregnant women with the Pfizer product (Abrysvo), which is intended to protect the baby during the first six months of life through the transfer of antibodies between mother and child. Crosses the placental barrier. In August 2023, Beyfortus, the commercial name for nirsevimab, a synthetic monoclonal antibody developed in the laboratories of Sanofi and AstraZeneca, was approved, this time injected directly into infants.
There are 43.12% left to read in this article. The remainder is reserved for subscribers.
1720515667
#babies #seniors #benefit #respiratory #syncytial #virus #vaccine
